RATIONALE: Low ALCs determined as part of a routine CBC may be an important clue to immunodeficiency. METHODS: The relationship between the routine CBC and a detailed lymphocyte analysis performed on the same day were studied in non-HIV positive patients presenting to the adult immunology clinic from 01/01/15 to 01/01/18. This interim analysis reports the relationship demonstrated in 122 patients. With one exception, the norms for the CD4, CD8 and CD19 and CD16/56 established by the clinical laboratory were used as the standards for normal or abnormal. The statistical significance of the data was calculated by Chi Square (X To investigate efficacy, tolerability and persistence of 5 brands of subcutaneous immunoglobulin (SCIG) in patients with primary immunodeficiency diseases (PIDD) in a real-world immunology physician practice setting. METHODS: We conducted a retrospective chart review of records from two immunology physician practices with pharmacy services for patients receiving SCIG in 2017. Data collected included demographics, disease characteristics, current and previous immunoglobulin (IgG) regimens, IgG serum levels, infection rates, adverse reactions and hospitalizations. Persistence was assessed as time from first dose of SCIG to discontinuation during the study period. RESULTS: Forty-two pts (mean age 52, 78% female) received various SCIG therapies for treatment of PIDD, including Cuvitru, Gammagard, Gamunex C, Hizentra and HyQvia. Patients were assessed monthly. Three patients had drug changes and 9/42 had drug dosage increases during the study period. Adverse reactions occurred in 31/42 (74%) of patients. The reactions were primarily mild, with infusion site reactions and headache most common. All were managed without drug discontinuation. Serious bacterial infection (pneumonia) was observed in 2/42 patients (4.7%), requiring short term hospitalization with resolution. Persistence with therapy was achieved in 98% of patients (41/42). CONCLUSIONS: Self-administration of various brands of SCIG for PIDD proved effective and tolerable, with manageable adverse reactions. Persistence of therapy was remarkedly high, suggesting positive patient experiences when managed through an immunology physician practice setting. 
: CD4523.6348, p <0.01; CD8512.4406 p< 0.001; CD195 4.4612 p< 0.05. ALC 1.2 to 2.0 k/ul vs. > 2.1k/ul. X 2 : CD45 2.1951 p < 0.05; CD195 8.9701, p <0.05; CD8 NS This indicates there is a good chance of detecting a low value for one of these lymphocyte subsets if the ALC<1.2 k/ul and also suggests that low CD4 and CD19 values 1.2 to 2.0 k/ul could be identified but the chances are significantly less. CONCLUSIONS: Recognizing patients were being investigated for a possible immune deficiency and not the general population, data demonstrates an ALC below 1.2 k/ul may reflect significantly low lymphocyte subsets. Other patient populations at risk for low ALCs include those receiving chemotherapy or XRT, HIV positivity, debilitated and age > 80 patients. 
METHODS:
We conducted a retrospective chart review of records from two immunology physician practices with pharmacy services for patients receiving SCIG in 2017. Data collected included demographics, disease characteristics, current and previous immunoglobulin (IgG) regimens, IgG serum levels, infection rates, adverse reactions and hospitalizations. Persistence was assessed as time from first dose of SCIG to discontinuation during the study period. RESULTS: Forty-two pts (mean age 52, 78% female) received various SCIG therapies for treatment of PIDD, including Cuvitru, Gammagard, Gamunex C, Hizentra and HyQvia. Patients were assessed monthly. Three patients had drug changes and 9/42 had drug dosage increases during the study period. Adverse reactions occurred in 31/42 (74%) of patients. The reactions were primarily mild, with infusion site reactions and headache most common. All were managed without drug discontinuation. Serious bacterial infection (pneumonia) was observed in 2/42 patients (4.7%), requiring short term hospitalization with resolution. Persistence with therapy was achieved in 98% of patients (41/42). CONCLUSIONS: Self-administration of various brands of SCIG for PIDD proved effective and tolerable, with manageable adverse reactions. Persistence of therapy was remarkedly high, suggesting positive patient experiences when managed through an immunology physician practice setting. 
In this study, we evaluate the change in quality of life score of patients trained for home infusion of C1 inhibitor for acute attacks. Quality of life was assessed before and up to 12 months after training using Profile of Mood State (POMS) and Short form from Health Survey (SF36). RESULTS: Seven HAE patients were recruited. There was improvement in the tension score and total mood score in the POMS scores. There was no statistically significant improvement in the SF-36 scores. CONCLUSIONS: There was a trend for quality of life to improve with home C1 infusion training. Statistical significance was not observed for most scores. This is likely due to small sample size. Home C1 inhibitor administration may improve quality of life in HAE patients. 1 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2 Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest Baptist Medical Center, Winston Salem, NC, 3 Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh. RATIONALE: Hypogammaglobulinemia (HGG) has been reported in more than 60% of lung transplant (LT) recipients and decreased pneumococcal titers (< 70% protective titers) have been reported in 86% of LT recipients following lung transplantation. We evaluated humoral immunity in subjects with end-stage lung disease prior to lung transplantation. METHODS: This is a single center prospective observational study of LT recipients. Pre-transplant IgG levels and pneumococcal titers were obtained within one year prior to transplant. Analysis was performed using non-parametric tests. RESULTS: 94 subjects were prospectively evaluated. The median age was 60 years (IQR, (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) ; 63.8% male and 90% Caucasian. 41.5% of subjects had idiopathic pulmonary fibrosis (IPF) and 25.5% had chronic obstructive pulmonary disease (COPD). HGG was present in 15% and decreased pneumococcal titers were present in 73% of subjects. Immunoglobulin levels were lower in subjects with COPD compared with other diseases (p50.0002). HGG (IgG < 700 mg/dl) occurred in 33.3% of COPD subjects and 2.6% of IPF, with no inter-group difference in the number of protective pneumococcal titers (p50.65). Subjects with lower pre-transplant IgG had fewer protective pneumococcal titers (p50.001), and pre-transplant prednisone dosing was inversely correlated with pre-transplant IgG levels (Spearman's rho5 -0.25, p50.01) and less than 2 protective pneumococcal titers (p50.005). Pre-transplant IgG levels were higher in those with CT scan-confirmed bronchiectasis. CONCLUSIONS: The type of underlying end-stage lung disease and prednisone dosing contribute to HGG and prednisone dosing impacts pneumococcal antibody titers. The presence of bronchiectasis is not associated with HGG in end-stage lung disease.
